We are live on ! Find out more
MIST icon

Milestone Pharmaceuticals
MIST

24 hedge funds and large institutions have $36.9M invested in Milestone Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

117% more capital invested

Capital invested by funds: $17M → $36.9M (+$19.9M)

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

26% more funds holding

Funds holding: 19 → 24 (+5)

1.97% more ownership

Funds ownership: 37.64% → 39.6% (+2%)

Holders
24
Holders Change
+5
Holders Change %
+26.32%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
3
Reduced
1
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$1.78M
2
KPF
K2 Principal Fund
Ontario, Canada
+$547K
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$179K
4
BFM
Boothbay Fund Management
New York
+$154K
5
SFI
Susquehanna Fundamental Investments
Pennsylvania
+$129K

Top Sellers

1
GTC
Ghost Tree Capital
New York
-$384K
2
Millennium Management
Millennium Management
New York
-$353K
3
SFM
Sphera Funds Management
Israel
-$125K
4
PM
Prosight Management
Texas
-$77K
5
BlackRock
BlackRock
New York
-$22.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$16.3M – – –
NHAS
2
Novo Holdings A/S
Denmark
$7.87M – – –
BC
3
Boxer Capital
California
$4.17M – – –
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$2.42M +$179K +55,571 +10%
Morgan Stanley
5
Morgan Stanley
New York
$2.26M +$1.78M +553,151 +1,223%
Invesco
6
Invesco
Georgia
$1.21M – – –
TCM
7
Tekla Capital Management
Massachusetts
$806K – – –
KPF
8
K2 Principal Fund
Ontario, Canada
$642K +$547K +169,730 New
BFM
9
Boothbay Fund Management
New York
$181K +$154K +47,800 New
SFI
10
Susquehanna Fundamental Investments
Pennsylvania
$151K +$129K +39,900 New
Barclays
11
Barclays
United Kingdom
$141K +$120K +37,266 +76,053%
SSA
12
Schonfeld Strategic Advisors
New York
$125K +$107K +33,200 New
California Public Employees Retirement System
13
California Public Employees Retirement System
California
$120K +$102K +31,800 New
SAMH
14
Shanda Asset Management Holdings
British Virgin Islands
$98K +$83.8K +26,000 New
TD Asset Management
15
TD Asset Management
Ontario, Canada
$87K – – –
Two Sigma Advisers
16
Two Sigma Advisers
New York
$79K +$67.3K +20,900 New
UBS Group
17
UBS Group
Switzerland
$51K – – –
FDCDDQ
18
Federation des caisses Desjardins du Quebec
Quebec, Canada
$49.1K – – –
Geode Capital Management
19
Geode Capital Management
Massachusetts
$48K +$41.2K +12,795 New
SFS
20
Sowell Financial Services
Arkansas
$30K +$25.8K +8,000 New
BlackRock
21
BlackRock
New York
$18K -$22.2K -6,899 -59%
TRCT
22
Tower Research Capital (TRC)
New York
$9K +$7.8K +2,423 New
CFGS
23
Concourse Financial Group Securities
Alabama
$1K – – –
GTC
24
Ghost Tree Capital
New York
– -$384K -208,733 Closed
Millennium Management
25
Millennium Management
New York
– -$353K -191,858 Closed
1
2

MIST Hedge Fund Activity: Q2 2020 in Review

24 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q2 2020, worth a combined $36.9M — up 117% from $17M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new MIST positions and 6 closed out — a net gain of 5 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $1.78M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $384K sold.

  • 24 institutional investors held Milestone Pharmaceuticals (MIST) as of Q2 2020, up from 19 in Q1 2020.
  • Funds reported $36.9M of Milestone Pharmaceuticals stock for Q2 2020, up 117% quarter-over-quarter.
  • 11 funds opened new Milestone Pharmaceuticals positions in Q2 2020 and 6 closed out, a net change of +5 holders.
  • The largest Milestone Pharmaceuticals buyer in Q2 2020 was Morgan Stanley, an estimated $1.78M added.
  • The largest Milestone Pharmaceuticals seller in Q2 2020 was Ghost Tree Capital, an estimated $384K sold.

Based on aggregated 13F filings for Q2 2020.